JPWO2021172498A1 - - Google Patents
Info
- Publication number
- JPWO2021172498A1 JPWO2021172498A1 JP2022503739A JP2022503739A JPWO2021172498A1 JP WO2021172498 A1 JPWO2021172498 A1 JP WO2021172498A1 JP 2022503739 A JP2022503739 A JP 2022503739A JP 2022503739 A JP2022503739 A JP 2022503739A JP WO2021172498 A1 JPWO2021172498 A1 JP WO2021172498A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C07K14/4708—Duchenne dystrophy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022141656A JP7292636B2 (ja) | 2020-02-28 | 2022-09-06 | エクソン51のスキッピングを誘導するアンチセンス核酸 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020033483 | 2020-02-28 | ||
PCT/JP2021/007286 WO2021172498A1 (ja) | 2020-02-28 | 2021-02-26 | エクソン51のスキッピングを誘導するアンチセンス核酸 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022141656A Division JP7292636B2 (ja) | 2020-02-28 | 2022-09-06 | エクソン51のスキッピングを誘導するアンチセンス核酸 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2021172498A1 true JPWO2021172498A1 (ja) | 2021-09-02 |
JPWO2021172498A5 JPWO2021172498A5 (ja) | 2024-03-04 |
Family
ID=77491251
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022503739A Pending JPWO2021172498A1 (ja) | 2020-02-28 | 2021-02-26 | |
JP2022141656A Active JP7292636B2 (ja) | 2020-02-28 | 2022-09-06 | エクソン51のスキッピングを誘導するアンチセンス核酸 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022141656A Active JP7292636B2 (ja) | 2020-02-28 | 2022-09-06 | エクソン51のスキッピングを誘導するアンチセンス核酸 |
Country Status (16)
Country | Link |
---|---|
US (2) | US20230140736A1 (ja) |
EP (1) | EP4112083A1 (ja) |
JP (2) | JPWO2021172498A1 (ja) |
KR (1) | KR20220145865A (ja) |
CN (1) | CN115210376A (ja) |
AU (1) | AU2021226089A1 (ja) |
BR (1) | BR112022017066A2 (ja) |
CA (1) | CA3173049A1 (ja) |
CL (1) | CL2022002279A1 (ja) |
CO (1) | CO2022013685A2 (ja) |
EC (1) | ECSP22074446A (ja) |
IL (1) | IL295967A (ja) |
MX (1) | MX2022010545A (ja) |
PE (1) | PE20230237A1 (ja) |
TW (1) | TW202200162A (ja) |
WO (1) | WO2021172498A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023168427A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
DE69033986T2 (de) | 1989-12-20 | 2003-03-13 | Antivirals Inc | Ungeladene, auf Morpholin basierende Polymere mit Chiralen, Phosphor enthaltenden Brücken zwischen den Untereinheiten |
JP2924179B2 (ja) | 1993-02-19 | 1999-07-26 | 日本新薬株式会社 | グリセロール誘導体,デバイス及び医薬組成物 |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
CA2507125C (en) | 2002-11-25 | 2014-04-22 | Masafumi Matsuo | Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
EP4272748A3 (en) | 2004-06-28 | 2024-03-27 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
JP2010505741A (ja) | 2006-05-10 | 2010-02-25 | エイブイアイ バイオファーマ, インコーポレイテッド | カチオン性のサブユニット間結合を有するオリゴヌクレオチドアナログ |
ES2694726T3 (es) | 2007-06-29 | 2018-12-26 | Sarepta Therapeutics, Inc. | Conjugados peptídicos específicos de tejido y métodos |
EP2203173B1 (en) | 2007-10-26 | 2015-12-23 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
WO2009064471A1 (en) | 2007-11-15 | 2009-05-22 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
JP5864257B2 (ja) | 2008-10-24 | 2016-02-17 | サレプタ セラピューティクス, インコーポレイテッド | Dmdのための複数のエキソンスキッピング組成物 |
ES2532634T5 (es) | 2008-10-27 | 2018-04-30 | Biomarin Technologies B.V. | Procedimientos y medios para el salto eficiente del exón 45 en el pre-ARNm de la distrofia muscular de Duchenne |
TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
KR102339196B1 (ko) | 2011-05-05 | 2021-12-15 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
CN104203289B (zh) | 2012-01-27 | 2020-11-03 | 比奥马林技术公司 | 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
JP6519842B2 (ja) | 2013-10-04 | 2019-05-29 | 国立大学法人神戸大学 | 福山型筋ジストロフィー治療用アンチセンス核酸 |
RU2730681C2 (ru) | 2014-03-12 | 2020-08-24 | Ниппон Синяку Ко., Лтд. | Антисмысловые нуклеиновые кислоты |
WO2016187425A1 (en) | 2015-05-19 | 2016-11-24 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
HUE057593T2 (hu) | 2015-08-05 | 2022-05-28 | Eisai R&D Man Co Ltd | Eljárás lényegében diasztereomeresen tiszta foszfor-diamidát oligomer elõállítására, az eljárással készített foszfor-diamidát oligomer és a foszfor-diamidát oligomert tartalmazó gyógyszerészeti készítmény |
CR20180233A (es) | 2015-10-09 | 2018-05-25 | Wave Life Sciences Ltd | Composiciones oligonucleotídicas y sus métodos |
EP3485015A4 (en) * | 2016-07-15 | 2020-07-29 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS OF MODULATION OF DYSTROPHINE TRANSCRIPT |
BR112019012647A2 (pt) | 2016-12-19 | 2019-11-19 | Sarepta Therapeutics Inc | conjugados de oligômero de salto de éxon para distrofia muscular |
WO2018118627A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
AU2017382773A1 (en) | 2016-12-19 | 2019-08-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
WO2019241385A2 (en) | 2018-06-13 | 2019-12-19 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystropy |
-
2021
- 2021-02-26 JP JP2022503739A patent/JPWO2021172498A1/ja active Pending
- 2021-02-26 CN CN202180017313.6A patent/CN115210376A/zh active Pending
- 2021-02-26 IL IL295967A patent/IL295967A/en unknown
- 2021-02-26 MX MX2022010545A patent/MX2022010545A/es unknown
- 2021-02-26 WO PCT/JP2021/007286 patent/WO2021172498A1/ja active Application Filing
- 2021-02-26 TW TW110107021A patent/TW202200162A/zh unknown
- 2021-02-26 BR BR112022017066A patent/BR112022017066A2/pt unknown
- 2021-02-26 US US17/802,720 patent/US20230140736A1/en active Pending
- 2021-02-26 PE PE2022001832A patent/PE20230237A1/es unknown
- 2021-02-26 KR KR1020227032708A patent/KR20220145865A/ko unknown
- 2021-02-26 CA CA3173049A patent/CA3173049A1/en active Pending
- 2021-02-26 AU AU2021226089A patent/AU2021226089A1/en active Pending
- 2021-02-26 EP EP21760603.7A patent/EP4112083A1/en active Pending
-
2022
- 2022-08-22 CL CL2022002279A patent/CL2022002279A1/es unknown
- 2022-08-25 US US17/895,186 patent/US11781140B2/en active Active
- 2022-09-06 JP JP2022141656A patent/JP7292636B2/ja active Active
- 2022-09-23 EC ECSENADI202274446A patent/ECSP22074446A/es unknown
- 2022-09-23 CO CONC2022/0013685A patent/CO2022013685A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022010545A (es) | 2022-09-21 |
CO2022013685A2 (es) | 2022-10-11 |
US11781140B2 (en) | 2023-10-10 |
US20230097387A1 (en) | 2023-03-30 |
BR112022017066A2 (pt) | 2022-11-16 |
PE20230237A1 (es) | 2023-02-07 |
WO2021172498A1 (ja) | 2021-09-02 |
KR20220145865A (ko) | 2022-10-31 |
CN115210376A (zh) | 2022-10-18 |
US20230140736A1 (en) | 2023-05-04 |
IL295967A (en) | 2022-10-01 |
ECSP22074446A (es) | 2022-10-31 |
CA3173049A1 (en) | 2021-09-02 |
JP2022180420A (ja) | 2022-12-06 |
EP4112083A1 (en) | 2023-01-04 |
AU2021226089A1 (en) | 2022-09-15 |
JP7292636B2 (ja) | 2023-06-19 |
CL2022002279A1 (es) | 2023-02-10 |
TW202200162A (zh) | 2022-01-01 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240222 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240222 |